Updates to the drug‐resistant mechanism of proteasome inhibitors in multiple myeloma
Y Bai, X Su - Asia‐Pacific Journal of Clinical Oncology, 2021 - Wiley Online Library
Proteasome inhibitors (PIs) have been a kind of backbone therapies for newly diagnosed as
well as relapsed or refractory myeloma patients in the last two decades. Bortezomib, the first …
well as relapsed or refractory myeloma patients in the last two decades. Bortezomib, the first …
Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma.
Y Bai, X Su - Asia-pacific Journal of Clinical Oncology, 2020 - europepmc.org
Proteasome inhibitors (PIs) have been a kind of backbone therapies for newly diagnosed as
well as relapsed or refractory myeloma patients in the last two decades. Bortezomib, the first …
well as relapsed or refractory myeloma patients in the last two decades. Bortezomib, the first …
Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma
Y Bai, X Su - Asia-Pacific journal of clinical oncology, 2021 - pubmed.ncbi.nlm.nih.gov
Proteasome inhibitors (PIs) have been a kind of backbone therapies for newly diagnosed as
well as relapsed or refractory myeloma patients in the last two decades. Bortezomib, the first …
well as relapsed or refractory myeloma patients in the last two decades. Bortezomib, the first …